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Nontypeable Haemophilus influenzae (NTHI) is an opportunistic pathogen that is an important cause of acute exacerbations of
chronic obstructive pulmonary disease (AECOPD). COPD is an inflammatory disease of the airways, and exacerbations are acute
inflammatory events superimposed on this background of chronic inflammation. Azithromycin (AZM) is a macrolide antibiotic
with antibacterial and anti-inflammatory properties and a clinically proven potential for AECOPD prevention andmanagement.
Relationships between AZM efficacy and resistance by NTHI and between bactericidal and immunomodulatory effects on NTHI
respiratory infection have not been addressed. In this study, we employed two pathogenic NTHI strains with different AZM sus-
ceptibilities (NTHI 375 [AZM susceptible] and NTHI 353 [AZM resistant]) to evaluate the prophylactic and therapeutic effects of
AZM on the NTHI-host interplay. At the cellular level, AZMwas bactericidal toward intracellular NTHI inside alveolar and
bronchial epithelia and alveolar macrophages, and it enhanced NTHI phagocytosis by the latter cell type. These effects correlated
with the strainMIC of AZM and the antibiotic dose. Additionally, the effect of AZM on NTHI infection was assessed in a mouse
model of pulmonary infection. AZM showed both preventive and therapeutic efficacies by lowering NTHI 375 bacterial counts in
lungs and bronchoalveolar lavage fluid (BALF) and by reducing histopathological inflammatory lesions in the upper and lower
airways of mice. Conversely, AZM did not reduce bacterial loads in animals infected with NTHI 353, in which case a milder anti-
inflammatory effect was also observed. Together, the results of this work link the bactericidal and anti-inflammatory effects of
AZM and frame the efficacy of this antibiotic against NTHI respiratory infection.
Nontypeable (noncapsulated)Haemophilus influenzae (NTHI)is a Gram-negative coccobacillus that is a common commen-
sal in the nasopharynx of healthy humans and is also an important
cause of respiratory infections, such as acute otitis media, otitis
media with effusion, community-acquired pneumonia, and exac-
erbations of chronic obstructive pulmonary disease (COPD) (1).
COPD is characterized by progressive and not fully reversible air-
flow limitation, accompanied by infiltration of the airways by neu-
trophils and mucus hypersecretion (2, 3). Acute exacerbations of
COPD (AECOPD) are episodes of increased respiratory and sys-
temic symptoms, mostly caused by bacterial and viral infections
(4). In this context, infection by NTHI is a marker of severe ob-
structive airflow and progression of the disease and has been as-
sociated with declines in lung function and with mortality (5).
Given that patients with frequent AECOPD have fast lung func-
tion declines, prolonged times of recovery, and a poor quality of
life (4, 6, 7), a reduction in AECOPDwould improve patient well-
being and survival (8–10).
Macrolide antibiotics are polyketide compounds with a 14-, 15-,
or 16-membered macrocyclic lactone to which one or more
amino and/or neutral sugars are attached.Macrolides include azi-
thromycin (AZM), a prototypical 15-membered compound with
favorable pharmacological properties (11). Features contributing
to AZM’s success as an antibiotic are its acid resistance, a short
time to achieve peak concentration, with a high level of accumu-
lation in phagocytes, and a long half-life (12–14). Macrolides in-
hibit bacterial growth by binding the 23S rRNA in the 50S subunit
of the bacterial ribosome, preventing the transfer of tRNA from
the A to the P site of the ribosome. Binding to the A site prevents
addition of an incoming amino acid-charged tRNA to the nascent
polypeptide chain, aborting polypeptide growth (15). In addition
to their direct antibacterial effect, macrolides are immunomodu-
lators, presenting anti-inflammatory activities on cells of the in-
nate and adaptive immunity and on structural cells (16–18). On
airway epithelia, macrolides positively regulate tight junctions
(19) and suppress the activation of NF-B, Sp1, and AP-1, leading
to a reduction of proinflammatory cytokines (20–25). On phago-
cytes, besides decreasing the secretion of proinflammatory cyto-
kines,macrolides stimulatemonocyte differentiation into alveolar
macrophages, improve phagocytic function, and favor expression
of the phagocytic mannose receptor in COPD patients (26–31).
Macrolides provide adequate coverage for the most frequently
identified pathogens in AECOPD (11). Several clinical studies
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have examined their potential for AECOPD prevention (32–37).
In particular, long-term prophylaxis with AZM in patients with
moderate to severe COPD has been associated with a significantly
decreased number of exacerbations and an improved quality of
life. Importantly, patients receiving AZM were less likely to be-
come colonized with respiratory pathogens but also were more
likely to become colonized with macrolide-resistant microorgan-
isms (32). In agreement with this notion, longitudinal studies of
nasopharyngeal carriage of respiratory bacteria in indigenous
Australian and Alaskan native children with bronchiectasis re-
vealed thatmacrolide resistancewas higher in Australian children,
who received more AZM, than in Alaskan children (34).
Although clinical data indicate the potential of AZM in the
management of chronic inflammatory airway disorders (9, 38,
39), the impact of AZM on infections caused by bacterial patho-
gens causing AECOPD is poorly understood. Moreover, the ob-
served increased macrolide resistance by colonizing respiratory
pathogens generates doubts about its long-term low-dose prophy-
lactic use. Independent studies with unrelated NTHI isolates dis-
playing different degrees of AZM susceptibility have shown a bac-
tericidal effect of AZM against intracellular NTHI (40–42), and
the therapeutic efficacy ofmacrolides has been suggested by use of
mouse and rat NTHI pulmonary infectionmodels (32, 43–46). In
this study,we questioned the effects of both prophylactic and ther-
apeutic uses of AZM, the relationship between NTHI AZM resis-
tance and administration effects, and the antimicrobial versus im-
munomodulatory effects of AZM on NTHI respiratory infection.
We employed two NTHI clinical isolates with different AZM sus-
ceptibilities (NTHI strain 375 [AZM sensitive] and NTHI strain
353 [AZM resistant]) to systematically evaluate the effects of pro-
phylactic and therapeutic administrations of AZM on (i) NTHI-
host cell interplay, by assessing adhesion, invasion/phagocytosis,
intracellular localization, and inflammatory responses on cul-
tured bronchial and alveolar epithelial cells and alveolar macro-
phages; and (ii) NTHI respiratory infection in vivo, by assessing
bacterial loads in lungs and bronchoalveolar lavage fluid (BALF),
as well as airway inflammatory lesions, in a murine intranasal
infection model. This work provides a context for a better under-
standing of the effects of AZM administration on NTHI respira-
tory infection.
MATERIALS AND METHODS
Bacteria, media, and growth conditions. NTHI 375 is an otitis media
isolate (47, 48). NTHI 353 is a clinical isolate from a sputum sample
recovered from a COPD patient at the Hospital Universitari Bellvitge
(HUB; Barcelona, Spain). Both NTHI strains were grown overnight at
37°C andwith 5%CO2 on chocolate-agar plates (bioMérieux) or on brain
heart infusion (BHI)-agar plates supplemented with 10g/ml hemin and
10 g/ml -NAD, referred to as sBHI-agar plates.
Antimicrobial agents and antibiotic susceptibility testing. AZM
(azithromycin dihydrate; Zitromax) was purchased from Pfizer and dis-
solved in sterile water. The susceptibilities of NTHI 375 and NTHI 353 to
AZM were determined by a standard MIC microdilution test, using the
criteria of the Clinical and Laboratory Standards Institute (CLSI) (49, 50).
Cell culture and bacterial infection. Human alveolar basal epithelial
carcinoma cells (A549; CCL-185) were maintained as described previ-
ously (51). Cells were seeded to 6  104 cells per well in 24-well tissue
culture plates for 32 h and then serum starved for 16 h before infection.
Mucoepidermoid pulmonary human epithelial carcinoma cells (NCI
H-292; ATCC CRL-1848) and MH-S murine alveolar macrophages
(ATCCCRL-2019)weremaintained inRPMI 1640 tissue culturemedium
supplemented with 10 mMHEPES, 10% heat-inactivated fetal calf serum
(FCS), and antibiotics (penicillin and streptomycin) in 75-cm2 tissue cul-
ture flasks at 37°C in a humidified 5% CO2 atmosphere. NCI H-292 cells
were seeded to 4  105 cells per well in 24-well plates 24 h before each
experiment. MH-S cells were seeded to 7  105 cells per well in 24-well
plates 16 h before each experiment. In all cases, 90% confluence was
reached at the time of infection.
NTHI infection was performed as previously described (51, 52). Bac-
teria were recovered with 1 ml phosphate-buffered saline (PBS) from a
chocolate-agar plate after growth for 16 h at 37°C and 5% CO2. Each
bacterial suspension was adjusted to an optical density at 600 nm (OD600)
of 1 in PBS (109 CFU/ml). A549 and NCI H-292 cells were infected in 1
ml Earle’s balanced salt solution (EBSS; Gibco) to obtain a multiplicity of
infection (MOI) of100:1. MH-S cells were infected in 1 ml RPMI 1640
supplemented with 10 mM HEPES and 10% FCS to obtain an MOI of
100:1, or 12:1 when necessary. For adhesion experiments, A549 and
NCI H-292 cells were incubated with bacteria for 30 min, andMH-S cells
were incubated with bacteria for 1 h. In all cases, wells were then washed 5
times with PBS, lysed with 300 l of PBS-0.025% saponin for 10 min at
room temperature, serially diluted, and plated on sBHI-agar plates. For
invasion assays, A549 and NCI H-292 cells were incubated with bacteria
for 2 h, washed 3 times with PBS, and incubated for 1 h with RPMI 1640
containing 10% FCS, 10 mM HEPES, and 200 g/ml gentamicin to kill
extracellular bacteria. For phagocytosis assays, MH-S cells were infected
for 1 h, washed 3 times with PBS, and incubated for 1 h with RPMI 1640
containing 10% FCS, 10 mM HEPES, and 300 g/ml gentamicin. In all
cases, cells were washed 3 times with PBS and lysed as described above.
When indicated, cells were pretreated with AZM (with various dose
ranges, depending on the NTHI strain and type of assay) or vehicle solu-
tion (sterile water) for 30 min; the drug/vehicle was then removed before
NTHI infection. AZM doses and regimens were selected according to
previous studies (40–42, 53) and according to the susceptibility to AZMof
the NTHI strains under study. Alternatively, cells were infected as de-
scribed above, and AZM (with various dose ranges, depending on the
NTHI strain and assay) or vehicle solution (sterile water) was added dur-
ing the gentamicin incubation period. These treatments did not induce
cytotoxicity on the three cell types tested, as verified by measuring the
release of lactate dehydrogenase and by microscopy (data not shown). In
all cases, parallel controls (CON)were performed: in adhesion assays, cells
did not receive AZM; and in invasion assays, cells were treated with gen-
tamicin but did not receive AZM. Adhesion, invasion, and phagocytosis
results are expressed as numbers of bacterial CFU per well. Each infection
assay was carried out in triplicate and on at least three independent occa-
sions (n 3).
Immunofluorescencemicroscopy.A549 cells were seeded on 13-mm
circular coverslips in 24-well tissue culture plates. Infections were per-
formed as described above, and infected cells were incubated in RPMI
1640 containing 10% FCS, 10mMHEPES, and 200g/ml gentamicin for
15 or 60 min in the absence (control) or presence of AZM. When indi-
cated, cells were washed three times with PBS and fixed with 3.7% para-
formaldehyde (PFA) in PBS, pH 7.4, for 15 min at room temperature.
Staining was carried out in 10% horse serum and 0.1% saponin in PBS.
NTHI 375 was stained with rabbit anti-NTHI serum diluted 1:600 (51).
Early endosomes were stained with goat anti-EEA1 (N-19) antibody
(Santa Cruz Biotechnology) diluted 1:50. Late endosomes were stained
with mouse monoclonal anti-human LAMP1 antibody (H4A3; Develop-
mental Studies Hybridoma Bank) diluted 1:100. DNA was stained with
Hoechst 33342 (Invitrogen) diluted 1:2,500. Donkey anti-rabbit conju-
gated to Cy2 and donkey anti-goat or donkey anti-mouse conjugated to
rhodamine were purchased from Jackson and were used as secondary
antibodies, diluted 1:100.
For immunofluorescence staining, fixed coverslips were washed twice
in PBS containing 0.1% saponin and once in PBS and then incubated for
30 min with primary antibodies in 10% horse serum, 0.1% saponin in
PBS. Coverslips were then washed twice in 0.1% saponin in PBS and once
in PBS and incubated for 30 min with secondary antibodies in 10% horse
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serum, 0.1% saponin in PBS. Finally, coverslips were washed twice in
0.1% saponin in PBS, once in PBS, and once in water and then mounted
on glass coverslips by use of Aqua-Poly/Mount (Polysciences). Samples
were analyzed with a Carl Zeiss Axioskop 2 Plus fluorescence microscope
and a Carl Zeiss Axio Cam MRm monochrome camera. An NTHI-con-
taining vacuole (NTHI-CV) was considered positive for EEA1 or LAMP1
when the marker was detected throughout the area occupied by the bac-
terium or around/enclosing the bacterium. To determine the percentage
of bacteria that colocalized with each marker, all bacteria located inside a
minimum of 150 infected cells were scored in each experiment. Results
were calculated from at least two independent experiments and are pre-
sented as means and standard deviations (SD) of the percentages of bac-
terium-subcellular marker association.
Secretionof IL-8.A549 cells weremaintained, seeded, and infected for
2 h, as described above. Cells were washed 3 times with PBS and incubated
for 6 h with fresh medium containing 100 g/ml gentamicin. Superna-
tants were collected from the wells, cell debris was removed by centrifu-
gation, and samples were frozen at80°C until use. Interleukin-8 (IL-8)
levels in the supernatants were measured by an enzyme-linked immu-
nosorbent assay (ELISA) (Abnova KA0115) with a sensitivity of 2 pg/
ml, performed according to the manufacturer’s instructions. When nec-
essary, cells were pretreated with 50 g/ml AZM or vehicle solution
(sterile water) for 30 min, and the antibiotic was removed before NTHI
infection. Alternatively, cells were pretreated with 1 M dexamethasone
(DEX; Sigma-Aldrich) for 2 h, which was kept during infection, including
the gentamicin incubation period (see above). In all cases, infections were
carried out in duplicate andon at least two independent occasions (n 2).
Results are expressed as themeans and SD of IL-8 levels (in picograms per
milliliter).
Mouse assays.Amousemodel ofNTHIpulmonary infectionwas used
as described previously (54, 55). CD1 female mice (18 to 20 g) aged 4 to 5
weeks were purchased from Charles River Laboratories (France), housed
under pathogen-free conditions at the Institute of Agrobiotechnology fa-
cilities (registration number ES/31-2016-000002-CR-SU-US), and used
at 22 to 25 g. Animal handling and procedures were performed in accor-
dance with the current European (directive 86/609/EEC) and national
(Real Decreto 53/2013) legislations, following the FELASA and ARRIVE
guidelines, and with the approval of the Universidad Pública de Navarra
(UPNa) Animal Experimentation Committee (Comité de Ética, Experi-
mentación Animal y Bioseguridad) and the local government. Following
the 3Rs principles, we first performed a pilot assay to determine the most
adequate AZM administration pattern in the mouse model. NTHI 375
was used for lung infection, and mice were randomly divided into the
following six groups (n	 5): (i) control (administered vehicle solution);
(ii) treated with AZM 24 h before infection; (iii) treated with AZM 12 h
before infection; (iv) treated with AZM 1 h before infection; (v) treated
with AZM 24 and 1 h before infection; and (vi) treated with AZM 24, 12,
and 1 h prior to infection and at 6 h postinfection (hpi). AZM treatments
were performed at doses of 100 mg/kg of body weight in 0.1 ml water and
administered by oroesophageal gavage (Popper & Sons Inc.). NTHI intra-
nasal infections were performed as described previously (55). Briefly, 20
l of an NTHI suspension containing5 109 CFU/ml (1 108 CFU/
mouse) was placed at the entrance of the nostrils until complete inhala-
tion by the mouse, which was previously anesthetized with ketamine-
xylazine (3:1). At 12 hpi, all mice were euthanized by cervical dislocation,
and lungs were aseptically removed, individually weighed in sterile bags
(Stomacher80; Seward Medical), and homogenized 1:10 (wt/vol) in PBS.
Each homogenate was serially 10-fold diluted in PBS, and 100 l of each
dilution was spread in triplicate on sBHI-agar plates to determine the
number of viable bacteria. Results are expressed as means 
 SD of indi-
vidual measurements of log10 CFU/lung. A second assay was designed to
study the relationship between AZM effects and susceptibility of the
NTHI infecting strain. Strains NTHI 375 and NTHI 353 were used sepa-
rately. Mice were randomly divided into the following three groups (n	
5) for each NTHI strain infection: (i) untreated control; (ii) animals
treated with three AZM doses, 24, 12, and 1 h prior to infection; and (iii)
animals treatedwith a single AZMdose, at 6 hpi. AZMoral administration
and NTHI intranasal infections were performed as detailed above. At 12
hpi, mice were euthanized, and BALF samples were obtained by perfusion
and collection of 0.7 ml of PBS, with the help of a sterile 20G (1.1-mm
diameter) Vialon intravenous catheter (Becton-Dickinson) inserted into
the trachea. Each recovered BALF fraction was serially 10-fold diluted in
PBS, and 100l of each dilution was spread on sBHI-agar plates to deter-
mine the number of viable bacteria. Results are expressed as means
 SD
of individual measurements of log10 CFU/BALF sample. In parallel, the
lungs were removed; the left one was processed for viable bacterial counts
(as detailed above), and the right lung was fixed in 10% neutral buffered
formalin for histological purposes. Heads and necks, containing upper
airways, larynxes, and tracheas, were also fixed in the same buffered for-
malin for histology. Uninfected mice receiving PBS, and AZMwhen nec-
essary, were used as controls.
Histopathology and lesion scores. Heads and necks were rinsed in
running tap water for 1 h and immersed in 5% nitric acid for 24 to 36 h
until complete decalcification, and 7 or 8 transaxial slices weremade every
3 to 4 mm, beginning at the nostrils and finishing in the caudal tracheas.
Transaxial slices and lungs were embedded in paraffin, and 4- to 6-m
sections were stained with hematoxylin and eosin (H&E) by standard
procedures and examined by microscopy to determine the presence and
extent of inflammatory lesions. Sections were examined blind as sets by a
trained veterinary pathologist (M. Barberán). Parameters characterizing
an acute inflammatory reaction in the upper airway, larynx, trachea, and
lung, including hemorrhages, hyperemia, polymorphonuclear cell
(PMN) infiltrates, and alveolar macrophages, were subjectively scored on
a scale of 0 to 3 (0, absent; 1, mild; 2, moderate; and 3, severe). For tissue
control, similar organs obtained from noninfected control and AZM-
treated mice were processed in a manner identical to that for the infected
tissues. The images were observed and digitalized using an Olympus
Vanox AHBS3 microscope coupled to an Olympus DP12 digital camera.
Statistical analysis. For cell infection, IL-8 secretion, and bacterial
loads in lungs and BALF samples, means
 SD were calculated, and sta-
tistical comparisons of means were performed using the two-tailed t test.
For histopathology scoring, means
 SD were also calculated, and statis-
tical comparisons were performed using one-way analysis of variance
(ANOVA) followed by Fisher’s protected least significant difference
(PLSD) multiple-comparison test. In all cases, P values of 0.05 were
considered statistically significant. Analyses were performed using the
Prism software, version 4 for PC (GraphPad Software), statistical package.
RESULTS
Selection of two NTHI clinical isolates with different suscepti-
bilities to AZM. We first selected two pathogenic NTHI isolates
with different levels of susceptibility to AZM. NTHI 375 is a child
otitis media isolate recovered from an ear sample (47, 48), whose
interplay with the host was previously characterized (51, 55, 56).
TheMIC of AZM for NTHI 375 is 0.25 g/ml, and accordingly, it
was classified as susceptible. NTHI 353 is a COPD strain isolated
froma sputum sample. TheMICofAZMforNTHI 353 is 8g/ml,
and it was classified as resistant. Both strains displayed compa-
rable growth rates in sBHI liquid culture (data not shown) and
infected cultured respiratory epithelial cells and alveolar mac-
rophages (see control data in Fig. 1 to 3; see Fig. S1 in the
supplemental material). Intranasal inoculation of CD1 mice
with similar doses of both NTHI strains rendered comparable
bacterial loads in lungs and BALF samples at 12 hpi (see control
panels in Fig. 4). Histopathological analysis of upper airways,
larynxes, tracheas, and lungs from mice infected intranasally
with NTHI 375 or with NTHI 353 rendered inflammatory le-
sions (Table 1). Lungs and airways from control mice instilled
with PBS did not show either significant inflammation or path-
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ological changes. In both NTHI 375- and NTHI 353-infected
mice, the upper airways showed some subepithelial and intra-
vascular neutrophils, and the lumens of the turbinates were
filled with a seropurulent exudate and sloughed lining epithe-
lial necrotic cells. Mild PMN infiltration of the lamina propria
and lumens containing red blood cells and PMNs were the
main findings in larynxes and tracheas. A tendency toward in-
creased inflammation in NTHI 375-infected compared to
NTHI 353-infected animals was apparent, with more accumu-
lation of PMNs in the upper airway, larynx, and trachea, al-
though the differences did not reach statistical significance
(Table 1). Lungs in infected mice showed areas of acute broncho-
pneumonia. In these areas, alveolar septawere thickenedwith edema
and hyperemic septal capillaries. Neutrophils, alveolarmacrophages,
and scattered small hemorrhages were observed in alveolar spaces.
Suppurative bronchitis and bronchiolitis with neutrophilic subepi-
thelial infiltrates and seropurulent exudates in the lumens were also
observed. Comparative analysis of scored lesions showed signifi-
cantly (P 0.0001) more recruitment of PMNs at the bronchi and
bronchioles of mice infected with NTHI 375 than at those infected
with NTHI 353. Conversely, both PMNs and alveolar macrophages
were found in larger proportions (P 0.05 and P 0.001, respec-
tively) at the alveoli of mice infected with NTHI 353 than at those of
mice infected with NTHI 375 (Table 1).
In sum, NTHI 375 and NTHI 353 are two pathogenic isolates
with different susceptibilities to AZM that are able to infect cul-
tured respiratory cells and the airways of mice, and these strains
were used to assess AZM efficacy in this work.
AZM efficacy against NTHI infection of airway epithelial
cells. We first evaluated the impact of AZM on the interface
between NTHI and airway epithelial cells. A549 human type II
pneumocytes were pretreated with 50 g/ml AZM, an AZM dose
previously shown to be immunomodulatory by inhibiting NTHI-
induced MUC5A expression and secretion (53). AZM was re-
moved before infection, and NTHI 375 adhesion and invasion
levels were quantified. NTHI 375 adhesion levels to A549 cells
were comparable for control and AZM-pretreated cells (Fig. 1A).
In contrast, cell pretreatment with 50 g/ml AZM reduced the
number of intracellular NTHI 375 organisms recovered from
A549 cells (P  0.005) (Fig. 1B). Similar effects were observed
when cells were pretreatedwith 25g/ml (P 0.01) or 12.5g/ml
(P 0.05) AZM (Fig. 1B). Controls (CON) consisted of cells that
did not receive AZM (adhesion assays) and cells treated with gen-
tamicin that did not receive AZM (invasion assays).
Given that the AZM doses used above have been shown to be
immunomodulatory (53), we asked if the observed reducedNTHI
375 invasion could be related to the impact of AZM on host cell
signaling. We showed previously that NTHI infection triggers
IL-8 secretion by A549 cells (54, 55). We sought to determine the
effect of pretreatment with 50 g/ml AZM on IL-8 secretion by
infected A549 cells. NTHI 375 induced secretion of comparable
IL-8 levels by untreated and AZM-pretreated cells. As a nonbac-
tericidal anti-inflammatory control, we employed the glucocorti-
coid dexamethasone (DEX), which decreased the amount of IL-8
secreted by NTHI 375-infected cells to the level displayed by con-
trol noninfected cells (Fig. 1C).
Although they were removed prior to infection in this study,
macrolides are likely to penetrate epithelial cells (41, 42, 45), and
the AZM doses used above are higher than the NTHI 375 AZM
MIC (MICAZM). Thus, we asked if the observed reduced NTHI
375 invasion could relate to a bactericidal effect of AZM against
intracellular bacteria. A549 cell infection with NTHI 375 was per-
formed in culture medium without supplementation of any anti-
biotic, followed by subsequent incubation in fresh medium sup-
plemented with gentamicin to kill extracellular bacteria and
without (CON) or with AZM to assess intracellular killing by
TABLE 1 Scores of histopathological lesions found in the airways of untreated or AZM-treated mice intranasally infected with NTHI 375 or
NTHI 353
Strain AZM treatmenta
Score (mean
 SD)b
Upper airways Larynx-trachea Lung
PMNs in
lumen
PMNs in
lamina
propria Hyperemia
PMNs in
lumen
PMNs in
lamina
propria
Bronchial
PMNs Hemorrhage
Alveolar
PMNs
Alveolar
macrophages
NTHI 375 Control 2.4
 0.3 2.3
 0.3 1.4
 0.2 1
 0.5 1.4
 0.2 2c,e 1.1
 0.5e 0d,f 0.13
 0.13d,f
Prior to infection 1.5
 0.4 1.2
 0.3 0.8
 0.1 0.2
 0.1 1 0.7
 0.2e 0.8
 0.2 1.1
 0.1f 0.6
 0.1
Postinfection 2.1
 0.4 1.6
 0.1 1.3
 0.3 0.3
 0.1 1.4
 0.2 0.6
 0.2e 0e 1.5
 0.3f 0.9
 0.2f
NTHI 353 Control 2
 0.1 1.6
 0.2 1.4
 0.2g 0.4
 0.1 1.2
 0.3 0.5
 0.1c 0.6
 0.2 1.3
 0.3d 1.2
 0.1d,h
Prior to infection 1.7
 0.4 1.5
 0.2 1.3
 0.2 0.4
 0.1 1.3
 0.3 1
 0.4 0.8
 0.3 1.2
 0.3 1.1
 0.1
Postinfection 1.8
 0.3 1.2
 0.2 0.6
 0.2g 0.5
 0.2 1.1
 0.1 0.5
 0.2 0.6
 0.2 0.4
 0.1 0.5h
a Control, animals administered vehicle solution; prior to infection, three AZM doses were administered, 24, 12, and 1 h before infection; postinfection, one AZM dose was
administered, at 6 h postinfection.
b Statistical comparisons of mean values were performed using one-way ANOVA followed by Fisher’s PLSD multiple-comparison test.
c More recruitment of PMNs at the bronchi of mice infected with NTHI 375 than at those of mice infected with NTHI 353 (P 0.0001).
d Larger proportions of PMNs and alveolar macrophages at the alveoli of mice infected with NTHI 353 than at those of mice infected with NTHI 375 (P 0.05 and P 0.001,
respectively).
e Reductions of inflammatory lesions for bronchial PMNs in mice treated with AZM prior to and after NTHI 375 infection (P 0.0005) and of lung hemorrhage in mice treated
with AZM after NTHI 375 infection (P 0.05), compared to controls.
f Larger numbers of PMNs (for mice treated prior to and after infection [P 0.01]) and alveolar macrophages (for mice treated postinfection [P 0.05]) at the alveoli of AZM-
treated animals than at those of controls infected by NTHI 375.
g Less hyperemia in the upper airways of mice treated with AZM after NTHI 353 infection than in those of control mice (P 0.05).
h Decreased recruitment of alveolar macrophages during NTHI 353 infection of animals treated with AZM postinfection compared to that of controls (P 0.0005).
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AZM. AZM was effective at reducing (P  0.001) the number of
intracellular bacteria (Fig. 1D).
To assess the relationship between AZM’s effect and the sus-
ceptibility of the infecting NTHI strain, we next quantified A549
cell adhesion and invasion for NTHI 353. Cell pretreatment with
AZM at 12.5, 25, or 50 g/ml did not modify NTHI 353 cell ad-
hesion or invasion levels compared to those for control cells not
receivingAZM(Fig. 1E and F).However, whenA549 cell infection
with NTHI 353 was performed and followed by subsequent incu-
bation in freshmedium supplementedwith gentamicin andAZM,
AZM was effective (P 0.0005) at reducing the number of intra-
cellular bacteria (Fig. 1G).
This AZM effect against NTHI could also be extended to NCI
H-292 bronchoepithelial cells. Pretreatment with AZM at 50
g/ml significantly (P 0.0001) reduced NTHI 375 invasion but
did not modify NTHI 353 invasion compared to that in control
cells. In contrast, addition of AZM at 50g/ml during gentamicin
incubation reduced both NTHI 375 and NTHI 353 intracellular
counts (P 0.0001 and P 0.005, respectively) (see Fig. S1 in the
supplemental material).
We and others previously described that NTHI invades epithe-
lial cells and localizes to an NTHI-containing vacuole (NTHI-
CV), a nonproliferative compartment with late endosome fea-
tures (51, 57, 58). Given thatmacrolides present good penetration
of lung tissue, are acid resistant, and accumulate in lysosome-like
compartments (11), we asked if AZM could modulate NTHI in-
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FIG 1 Effect of AZM administration on NTHI infection of A549 human respiratory epithelial cells. Controls were as follows: in adhesion assays, cells did not
receive AZM; and in invasion assays, cells were treated with gentamicin but did not receive AZM. (A and E) Effects of AZM pretreatment on NTHI 375 (A) and
NTHI 353 (E) adhesion to A549 type II pneumocytes. Cells were pretreated with AZM at 12.5, 25, or 50 g/ml. The antibiotic was removed before NTHI
infection. Both strains presented similar adhesion rates for AZM-pretreated and control (CON) cells. (B and F) Effects of AZM pretreatment on NTHI 375 (B)
and NTHI 353 (F) invasion of A549 cells. Cells were pretreated with AZM at 12.5, 25, or 50g/ml. Mean numbers of NTHI 375 entry into AZM-pretreated cells
were significantly lower (*) than those obtained for control (CON) cells (for 12.5 g/ml, P 0.05; for 25 g/ml, P 0.01; and for 50 g/ml, P 0.005). Mean
numbers of NTHI 353 invasion did not vary upon AZM pretreatment. (C) Effect of AZM or dexamethasone (DEX) on the NTHI 375-mediated inflammatory
response, measured by the level of IL-8 secreted into the supernatant by A549 cells. CON, uninfected cells that did not receive AZM; untreat, cells infected with
NTHI 375 that did not receive AZM. Quantification of IL-8 was performed by ELISA at 8 h postinfection. AZM did not show an anti-inflammatory effect under
the conditions tested. (D andG) Effects of AZMon intracellularNTHI 375 (D) andNTHI 353 (G). A549 cells were infected, and 50g/mlAZMwas added during
cell incubation with gentamicin (Gm). In both cases, the number of intracellular bacteria was significantly lower (P 0.001 and P 0.0005, respectively) for
AZM-treated cells than for control cells.
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tracellular compartmentalization. We determined the percentage
of intracellular bacteria that colocalized with the EEA1 or LAMP1
endocytic marker. Table S1 in the supplemental material shows
the means
 SD of the percentages of bacterium-marker associa-
tion. We did not detect significant differences between EEA1-
or LAMP1-bacterium colocalization levels between control and
AZM-treated infected cells. At 15min post-gentamicin treatment,
a tendency toward an increased percentage of EEA1-NTHI 375
colocalization in AZM-treated cells was apparent but did not
reach statistical significance.
In summary, these results suggest a bactericidal effect of AZM
onNTHI 375 andNTHI 353 organisms inside epithelial cells. This
effect may relate to the AZM susceptibility of the infecting strain.
Similar observations were obtained for A549 andNCIH-292 cells.
Intracellular bacteriological effects of various AZM concen-
trations on NTHI epithelial infection. An AZM concentration
higher than theMICs of strainsNTHI 375 andNTHI 353was used
in the assays described above and showed an intracellular bacteri-
ological effect on epithelial cells. Note that an assessment of the
intracellular bactericidal effect of clarithromycin (CLR) against
NTHI inside NCI H-292 bronchoepithelial cells previously re-
vealed that CLR reduced the number of viable bacteria at less than
half the MIC (45). Considering this evidence, we hypothesized
that the bactericidal effect of AZMagainst intracellularNTHImay
relate to the antibiotic dose used and to the MIC of the infecting
strain. We compared the intracellular bacteriological effects at
various AZM concentrations for both NTHI 375 and NTHI 353.
As shown in Fig. 2A, AZM significantly reduced the number of
intracellular viable NTHI 375 organisms at AZM concentrations
corresponding to the NTHI 375MIC (P 0.05) and higher (for 1
g/ml AZM, P  0.001; for 4 g/ml AZM, P  0.005; and for 8
g/ml AZM, P  0.0005). AZM also significantly reduced the
number of intracellular NTHI 353 organisms when an AZM dose
corresponding to the NTHI 353 MIC was used (P  0.05) (Fig.
2B). AZM concentrations lower than the NTHI 375 or NTHI 353
MIC did not significantly reduce intracellular bacterial counts.
To further support the notion of a bactericidal effect of AZM
on intracellular NTHI, we pretreated A549 cells with AZM at con-
centrations unable to reduce intracellular bacterial loads and eval-
uated bacterial invasion. ForNTHI 375, cells pretreatedwithAZM
at 0.0625 and 0.125 g/ml did not reduce bacterial invasion (Fig.
2C). For NTHI 353, cells pretreated with AZM at 0.25 g/ml did
not decrease the intracellular bacterial counts (Fig. 2D). In agree-
ment, NCI H-292 cell pretreatment with the highest AZM con-
centrations unable to reduce intracellular bacterial loads in A549
cells rendered NTHI 375 and NTHI 353 invasion rates similar to
those obtained for control cells (see Fig. S1 in the supplemental
material).
Together, these data indicate that the effect of AZM on intra-
cellular bacteria depends on the AZMdose and the bacterial MIC,
with AZM being able to reduce intracellular NTHI inside respira-
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FIG 2 Intracellular bactericidal effects of various AZM concentrations against NTHI infection of A549 cells. Controls were as follows: cells were treated with
gentamicin but did not receive AZM. (A) A549 cells were infected with NTHI 375. Various AZM concentrations were added during infected cell incubation with
gentamicin. The amount of intracellular NTHI 375 decreased significantly upon treatment with AZM at 1, 4, 16, and 32MIC (P 0.05, P 0.001, P
0.005, and P 0.0005, respectively) compared to that in control (CON) cells. (B) A549 cells were infected with NTHI 353. Various AZM concentrations were
added during infected cell incubation with gentamicin. Intracellular viable bacterial numbers decreased significantly when NTHI 353 was treated with AZM at
1MIC (P 0.05). (C) Effect of A549 cell pretreatment with two AZM concentrations unable to kill intracellular NTHI 375 (0.0625 and 0.125 g/ml). AZM
was removed, and infectionwas performed inAZM-free cell culturemedium.Mean numbers forNTHI 375 entry intoAZM-pretreated cells were similar to those
obtained for control cells. (D) Effect of A549 cell pretreatmentwithAZMat 0.25g/ml, a concentration unable to kill intracellularNTHI 353. AZMwas removed,
and infection was performed in AZM-free cell culturemedium.Mean numbers for NTHI 353 entry into AZM-pretreated cells were similar to those obtained for
control cells.
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tory epithelial cells when used at levels corresponding to the MIC
of the infecting strain.
Effect ofAZMonNTHIalveolarmacrophage infection.AZM
has been shown to have a short time to achieve peak concentra-
tion, with a high level of accumulation in phagocytes (14, 46), and
to improve macrophage phagocytic uptake of bronchial epithelial
cells and heat-killed nonpathogenic bacteria (26–28).We assessed
the effect of AZM on NTHI infection of MH-S alveolar macro-
phages. As described above, MH-S cells were first pretreated with
50 g/ml AZM, which was removed prior to infection by NTHI
375 orNTHI 353. Phagocytosis quantification showed a reduction
of counts for both strains in AZM-pretreated compared to control
cells (P 0.005 for NTHI 375 and P 0.0005 for NTHI 353). A
bacterial decreasewas also observed for cells infected byNTHI 375
or NTHI 353 when AZM was added during the gentamicin incu-
bation time (P  0.0005) (Fig. 3A and B). As indicated above,
controls (CON) consisted of cells treated with gentamicin that did
not receive AZM.
To further explore this observation, together with the previ-
ously described improvement ofmacrophage phagocytic function
due to AZM use (26–28), we pretreated MH-S cells with AZM at
concentrations unable to reduce intracellular bacterial loads and
then evaluated bacterial phagocytosis. The amounts of NTHI 375
phagocytosis by cells pretreated with AZM at 0.125 and 0.0625
g/ml, i.e., concentrations that do not modify bacterial counts
when added at the onset of gentamicin treatment, were higher
than those for control cells (P 0.01 and P 0.05, respectively)
(Fig. 3C). For NTHI 353, when cells were pretreated with AZM at
0.0625, 0.125, and 0.25 g/ml, i.e., doses unable to modify bacte-
rial counts when added during gentamicin incubation, phagocy-
tosis was similar to that obtained for untreated cells (data not
shown). The MH-S phagocytic rate for NTHI 353 was approxi-
mately twice that observed for NTHI 375 (see control data in Fig.
3A and B). This observation prompted us to hypothesize that our
standard phagocytosis assay is not sensitive enough to reveal a
potential effect of AZM on macrophage phagocytic function to-
ward NTHI 353. Following this notion, we lowered the NTHI 353
infecting dose to an MOI of 12:1 and observed that NTHI 353
phagocytosis by cells pretreated with 0.25 g/ml AZMwas higher
(P 0.0001) than that by control cells (Fig. 3D).
In conclusion, these results show that AZM has a bactericidal
effect on bacteria inside alveolar macrophages. Moreover, AZM
concentrations unable to kill intracellular NTHI may enhance al-
veolarmacrophage phagocytic function and therefore increase the
NTHI uptake rate.
Bactericidal and anti-inflammatory effects of AZMadminis-
tration on mouse pulmonary infection with NTHI. Finally, we
sought to determine the impact of oral administration of AZM in
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FIG3 Effect of AZMonNTHI infection ofMH-S alveolarmacrophages. Cells were left untreated (CON; cells treatedwith gentamicin that did not receive AZM),
pretreated with AZM at 50 g/ml, or infected and treated with AZM at 50 g/ml during cell incubation with gentamicin. Mean numbers for NTHI 375 (A) and
NTHI 353 (B) phagocytosis are shown. (A)NTHI 375 phagocytosis levels byAZM-pretreated cells and cells treatedwithAZMduring gentamicin incubationwere
significantly lower than those obtained for control cells (P  0.005 and P  0.0005, respectively). (B) Mean numbers for NTHI 353 phagocytosis by AZM-
pretreated cells and cells treated with AZM during gentamicin incubation were significantly lower than those obtained for control cells (P 0.0005). (C) Cells
were left untreated or pretreated with AZM at 0.0625 or 0.125 g/ml, i.e., concentrations unable to kill intracellular NTHI 375; drug/vehicle was removed prior
to infection.Mean numbers forNTHI 375 phagocytosis by cells pretreatedwithAZMwere significantly higher than those obtained for control cells (P 0.05 and
P 0.01, respectively). (D) Cells were left untreated or pretreated with AZMat 0.0625, 0.125, or 0.25g/ml, i.e., concentrations unable to kill intracellular NTHI
375; drug/vehicle was removed prior to infection. Infection was performed at an MOI of12:1. Mean numbers for NTHI 353 phagocytosis by cells pretreated
with AZM at 0.25 g/ml were significantly higher than those obtained for control cells (P 0.0001).
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vivo by using a mouse model system of NTHI respiratory infec-
tion. First, we used different single-dose regimens of oral AZM
(100 mg/kg) before infection with NTHI 375, or we used a com-
bined regimen (consisting of three AZM administrations prior to
infection plus one at 6 hpi). The results indicated that only the
combined AZM regimen was effective against NTHI 375 lung in-
fection in mice (P 0.01) (see Fig. S2 in the supplemental mate-
rial). Accordingly, a second experiment was conducted separately
with strains NTHI 375 and NTHI 353, using (i) a combined AZM
regimen before (24, 12, and 1 h) infection to mimic the
prophylactic use of AZM and (ii) a single AZM treatment at 6 hpi
to mimic its therapeutic use. AZM was effective against infection
by the AZM-susceptible strain NTHI 375 (Fig. 4A and B) but not
against the AZM-resistant strainNTHI 353 (Fig. 4C andD). Thus,
both AZM regimens provided significant reductions of NTHI 375
pulmonary infection compared to the case for control mice (for
the regimen prior to infection, P 0.0001; and for the postinfec-
tion regimen, P 0.05) (Fig. 4A), suggesting not only a therapeu-
tic but also a prophylactic effect of AZM against NTHI 375 infec-
tion. FewerNTHI 375 bacteria were also recovered from the BALF
ofmice treatedwith AZM;whenmice received AZMbeforeNTHI
375 infection, this decrease was significant (P 0.005) compared
to controls (Fig. 4B).
Microscopy scores of average histopathological lesions in sam-
ples from mice infected with NTHI 375 or NTHI 353 were also
determined along the respiratory tract and compared for un-
treated and AZM-treated mice. Lungs and airways from control
mice instilled with PBS did not show significant inflammation or
pathological changes, independently of the absence or presence of
AZM. Comparative analysis of scored lesions in upper and lower
airways of mice infected with NTHI 375 showed lower inflamma-
tory reaction scores for AZM-treated mice, especially those
treated before the infection (Fig. 5). This reduction of inflamma-
tory lesions was significant for bronchial PMNs in both mice
treated with AZM preinfection and those treated postinfection
(P 0.0005) and for lung hemorrhage in mice treated with AZM
postinfection (P  0.05) (Table 1). Conversely, we observed sig-
nificantly larger numbers of PMNs (for mice treated pre- or
postinfection [P  0.01]) and alveolar macrophages (for mice
treated postinfection [P  0.05]) at the alveoli of AZM-treated
animals than at those of controls infected by NTHI 375 (Table 1).
We also observed a dampening effect of AZM on respiratory in-
flammatory lesions in mice infected by NTHI 353, which, in gen-
eral terms, weremilder than those observed inNTHI 375-infected
animals. We observed significantly (P  0.05) less hyperemia in
the upper airways of mice treated with AZM postinfection than in
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FIG 4 Effect of AZM administration on bacterial loads in CD1 mice infected by NTHI. Mice were infected intranasally with108 bacteria/mouse. AZM (100
mg/kg/dose) was administered orally. Controls were as follows: animals were administered vehicle solution but did not receive AZM. Bacterial counts were
determined at 12 hpi for lungs (log10 CFU/lung) (A and C) and BALF (log10 CFU/BALF sample) (B and D). (A) Impact of AZM on NTHI 375 counts in lungs.
NTHI 375 countswere significantly lower inmice treatedwithAZMprior to (1, 12, and 24hbefore infection) and/or after (6 hpi) infection than in control (CON)
mice (P 0.0001 and P 0.05, respectively). (B) Effect of AZMonNTHI 375 bacterial counts in BALF samples. NTHI 375 counts were significantly (P 0.005)
lower inmice treated with AZMprior to infection than in controlmice. (C andD) Impacts of AZMuse onNTHI 353 bacterial counts in lungs (C) and BALF (D).
NTHI 353 counts were similar for all mouse groups.
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those of control mice, and the recruitment of alveolar macro-
phages during NTHI 353 infection was decreased in these AZM-
treated animals (P 0.0005) compared to controls (Table 1).
In sum, these results indicate that administration of three pro-
phylactic doses of AZM at 100 mg/kg facilitates pulmonary clear-
ance of the AZM-susceptible strain NTHI 375 but not of the
AZM-resistant isolateNTHI 353. The same effectwas observed for
the use of one therapeutic dose of AZM (100 mg/kg). AZM ad-
ministration reduced NTHI-triggered inflammation to different
extents, depending on the infecting strain, with this anti-inflam-
matory effect being more prominent in NTHI 375-infected than
NTHI 353-infected animals. These observations suggest a link be-
tween the antimicrobial and anti-inflammatory effects of AZMon
NTHI respiratory infection, which may be modulated by the
MICAZM of the infecting strain.
DISCUSSION
This study delineates the effect of AZM administration on respi-
ratory infection byNTHI. By using conditionsmimicking preven-
tive or therapeutic AZM administration in cultured respiratory
cell and in vivo model systems, we have established the impact of
this macrolide on a number of properties related to NTHI patho-
genesis in the respiratory tract. NTHI is largely associated with
chronic infection in COPDpatients and with AECOPD frequency
(4), and clinical evidence suggests a potential for AZM in the pre-
vention and management of AECOPD (32). Despite its potential
benefit, AZM seems to increase carriage of macrolide-resistant
bacteria, thereby generating doubts about long-term administra-
tion of AZM (32, 34). Based on the clinical evidence, understand-
ing the impact of AZMon infection byNTHIwill informpotential
changes in clinical guidelines. Moreover, given that long-term
low-dose preventive administration of AZM is under consider-
ation, it is important to determine the impacts of both prophylac-
tic and therapeutic uses of AZM on NTHI infection. Our system-
atic use of in vitro and in vivo model systems allowed us to
comprehensively compareAZM’s effects on infection by anAZM-
susceptible and an AZM-resistant NTHI clinical isolate and to
establish associations between AZM efficacy, dose, bacterial MIC,
and bactericidal/immunomodulatory properties.
At the cellular level, our results show a bactericidal effect of
AZM on intracellular NTHI, possibly related to AZM’s ability to
penetrate tissues and cells. This is an interesting notion regarding
NTHI infection treatment, given that NTHI invades epithelial
cells and can persist intracellularly (51, 58). An antimicrobial ef-
fect on intracellular bacteria was observed for NTHI 375 and
NTHI 353 and was related to the AZM dose and the MIC of the
infecting strain. The efficacy of AZM to clear intracellular NTHI
was previously compared to those of a whole range of different
antibiotic treatments (41, 42). To our knowledge, this is the first
report of AZM’s efficacy on intracellular NTHI where both AZM
doses and the MIC of the infecting strain have been considered
systematically. CLR’s intracellular bacteriological effects at vari-
ous antibiotic concentrations were previously evaluated for a
CLR-resistant NTHI strain, establishing that CLR could reduce
the number of bacteria inside NCI H-292 cells at less than half the
MIC (45). In the present study, we observed a correlation between
a significant reduction of bacteria inside A549 cells and theMICof
AZM for both NTHI 375 and NTHI 353. A comparison between
previous CLR (45) and current AZM data suggests an advanta-
geous use of CLR, which is able to reduce intracellular bacterial
counts at less than half the MIC, compared to AZM, which is
able to do so at a dose close to the strain MIC. Overall, the data
A
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AZM pre-treated 
NTHi375 infected
FIG 5 Effect of AZM on histopathological findings in upper airways of mice infected intranasally with NTHI 375. Tissue sections were stained with H&E. (A)
Severe lesions in upper airway from an untreatedmouse infected with NTHI 375. The lumen of the turbinate is fully filled with exudate. (B) Detail of the lumen,
showing serous exudate, erythrocytes, neutrophils, and scanty detached epithelial cells. (C)Mild lesions in upper airway fromanAZM-pretreatedmouse infected
with NTHI 375, showing small amounts of seropurulent luminal exudate. (D) Detail of the exudate from panel C.
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indicate that macrolides present the potential to eradicate in-
tracellular susceptible and resistant NTHI, and this ability may
contribute to preventing persistent and recurrent infections by
this pathogen.
Besides its antimicrobial effect, AZM has been shown to have
additional properties on host cells. First, AZM is a lysosomotropic
antibiotic, whose accumulation is associated with a vacuolation of
endosomes in macrophages and fibroblasts (59, 60). Our immu-
nofluorescence-based analysis did not reveal significant differ-
ences in the percentage of NTHI-EEA1/LAMP1 colocalization in
A549 cells, limiting a possible AZM-triggered modulation of
NTHI’s intracellular location. Second, AZM has been shown to
suppress inflammation in a range of cell model systems (20, 21,
23–25, 29, 30, 61). Moreover, AZM suppresses inflammation in-
duced by Pseudomonas aeruginosa (62), Fusobacterium nucleatum
(63), and Klebsiella pneumoniae (64). Although AZM has been
suggested to dampen inflammation during NTHI infection (53,
65), it should be noted that these two studies were carried out by
stimulating host cells with bacterial extracts, which may differ
substantially from using viable bacteria. We did not observe any
modification in the level of NTHI-triggered IL-8 secreted by
AZM-treated A549 cells compared to untreated cells. However,
our results may not exclude AZM-driven modulation of other
inflammatory parameters upon NTHI cell infection. Third, AZM
has been shown to improve macrophage phagocytic function of
bronchial epithelial cells and heat-killed nonpathogenic bacteria
(26–28). In agreement, we observed that cell pretreatment with
sublethal AZM doses may also improve macrophage phagocytic
function to ingest NTHI. These data should be considered in the
context of the COPD patient, given that several studies have re-
ported alterations in alveolar macrophage activity in COPD pa-
tients (66–69). These alterations include defective immune re-
sponsiveness in terms of diminished IL-8, tumor necrosis factor
alpha (TNF-), and IL-1 responses (69), impaired phagocytosis
(66, 68), and dysfunctional innate responses associated with im-
paired Toll-like receptors (TLRs) (67).
AZM also displayed efficacy by reducing bacterial loads in
lungs and BALF duringmouse respiratory infection when admin-
istered before and after intranasalNTHI administration. This bac-
terial clearing effect was shown to correlate with the MIC of AZM
of the infecting strain and with the number of AZM doses admin-
istered. To our knowledge, this is the first report of efficacy for
AZM administered prior to infection, mimicking its prophylactic
use. AZM’s therapeutic potential has been proven previously in
mouse and rat models by using different AZM-susceptible NTHI
isolates and respiratory infection routes (43, 44, 46, 70). We
showed here that under the conditions tested, AZM treatment did
not reduce lung and BALF bacterial loads of the AZM-resistant
isolate NTHI 353, indicating that AZM efficacy relates to the sus-
ceptibility of the infecting strain. Given the observed increasing
carriage rates of macrolide-resistant bacteria after AZM adminis-
tration, this observation should be taken into consideration by
clinicians.
Besides their bactericidal efficacy, evidence suggests that mac-
rolides present immunomodulatory properties in vivo. AZM pre-
vents the progression of lung inflammation in Acinetobacter bau-
mannii-infected mice, without having an antimicrobial effect
(71), and alters the macrophage phenotype and pulmonary com-
partmentalization during P. aeruginosa lung infection (72).More-
over, CLR displays efficacy against an intubation model of in-
duced pneumonia caused by a CLR-resistantNTHI strain inmice,
with reductions of bacterial loads and inflammation in CLR-
treated animals (45). Histopathological examination revealed a
reduction of inflammatory lesions in NTHI-infected animals
treatedwith AZM, to different extents, depending on the infecting
strain. Differences between strains may relate to the differential
bactericidal effect of the macrolide. AZM caused a reduction of
NTHI 375 loads, which may have contributed to the observed
reduced inflammatory lesions due to the lowering of the inflam-
matory stimulus. However, AZM did not reduce NTHI 353 loads,
whichmay have contributed to keeping inflammatory lesions due
to the maintenance of the inflammatory stimulus. Differences be-
tween strains may also relate to the observed slight inflammatory
differences between them. NTHI 375-triggered lesions were more
severe in the upper airways, and NTHI 353-triggered lesions were
more severe in the lungs, which may relate to differences in their
pathological origins, i.e., otitis and COPD, respectively. Even
though NTHI isolates were chosen as representative of AZM re-
sistance and sensitivity, we acknowledge that this inflammatory
difference may be a limitation of the present study. Surprisingly,
AZM increased the number of PMNs and macrophages in the
alveoli of NTHI 375-infected animals. We speculate that AZM’s
bactericidal efficacy against NTHI 375 reduces lung and BALF
bacterial loads, facilitating the exposure/release of pathogen-asso-
ciated molecular patterns (PAMPs) and the subsequent recruit-
ment of phagocytes. AZM also seems to increase phagocytic func-
tion by phagocytes, which would amplify bacterial clearance and,
ultimately, further reduce bacterial counts. Together, the data
show that AZM displays efficacy against mouse respiratory infec-
tion by an AZM-sensitive NTHI strain, causing reductions of bac-
terial loads and inflammation, which aligns with observations
made for NTHI and CLR (45). Moreover, AZM mildly prevents
the progression of lung inflammation inNTHI 353-infectedmice,
without having an antimicrobial effect, aligningwith observations
made for A. baumannii and AZM (71). AZM’s anti-inflammatory
effect on infectedmice supports the notion of a potential benefit of
this antibiotic on respiratory patients with inflammatory disor-
ders, added to its bactericidal effect dependent on the MIC of
AZM of the infecting strain.
Clinical studies have suggested that long-term low-dose AZM
used to prevent and/or manage chronic inflammatory airway dis-
orders, such as AECOPD, may be beneficial but also may increase
the rate of macrolide resistance by colonizing opportunistic
pathogens. In fact, a recent meta-analysis warns of the adverse
effects of long-term AZM use in patients with chronic lung dis-
eases (73). Interestingly, the use of AZM for AECOPD prevention
is currently under debate, but without a comprehensive under-
standing of the effect of AZM on the progression of respiratory
infection by bacterial pathogens frequently associated with
AECOPD. The present study sheds light on this matter by eval-
uating the effect of AZM on infection by NTHI, considering the
relationship between antibiotic dose and the MIC of the infect-
ing strain, and shows that AZM’s efficacy against NTHI respi-
ratory infection very much relates to the MIC of the infecting
strain. In conclusion, AZM has the potential to be used as an
interference strategy to abolish NTHI-host interplay, which
would limit NTHI adaptation, therefore preventing coloniza-
tion and/or pathogenicity.
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